»ï¼ºÃ¢¿øº´¿ø Samsung Changwon Gynecologic Oncology Precision Medicine Meeting : 2019-01-19±³À°ÀÏÀÚ : 2019-01-19
±³À°Àå¼Ò : »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀǽÇ
±³À°ÁÖÁ¦ :
Samsung Changwon Gynecologic Oncology Precision Medicine MeetingÁÖÃÖ±â°ü : »ï¼ºÃ¢¿øº´¿ø
´ã´çÀÚ : ±è¹Î±Ô
¿¬¶ôó : 055-233-5290
À̸ÞÀÏ :
minkyu72.kim@samsung.com ±³À°Á¾·ù : »êºÎÀΰú
Âü¼®¿¹»óÀοø : 50¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
°æ»ó³²µµ±³À°½Ã°£ : 6 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 70,000¿ø
ºñ°í »çÀüµî·Ï: 5¸¸¿ø(Àü°øÀÇ/°£È£»ç 3¸¸¿ø) ÇöÀåµî·Ï: 7¸¸¿ø(Àü°øÀÇ/°£È£»ç 3¸¸¿ø)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 11:50~11:55 Opening Remark: À¯Àü¼º ºÎÀÎ ¾Ï ȯÀÚ´Â ¾ÕÀ¸·Î ¾î¶»°Ô Ä¡·á¹ÞÀ» °ÍÀΰ¡? ±è¹Î±Ô(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 11:55~12:20 Ovary cancer ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 12:20~12:45 Breast cancer À̼®¿µ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 12:45~13:10 Non-Ovary/Non-Breast BRCA related cancer À¯ÇåÁ¾(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 13:10~13:35 Non-EM Gynecologic malignancy ÃÖ¹Îö(Â÷ÀÇ°úÇдë)
Åä·Ð 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 13:35~13:40 Discussion, Q & A ()
±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 13:40~14:05 Bridging Bench to Clinic:Scientist's Experience in GY Maligancy ÇÑÈñµ¿(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 14:05~14:30 From ¡°Synthetic lethality¡± till PARPi À̼ºÁ¾(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 14:30~14:55 Oncologic Urgency/Emergency/Complication Management À̹οµ(¼øõÇâÀÇ´ë)
Åä·Ð 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 14:55~15:00 Discussion ()
ÈÞ½Ä 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 15:00~15:05 Coffee Break ()
±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 15:05~15:30 Pursuit of Better Through Comprehensive Genomic Profiling °¡¼ÒÁ¤(Çѱ¹ ·Î½´)
±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 15:30~15:55 Microsatellite instability (MSI) test as a screening for Lynch syndrome and biomarker for Immunotherapy ±èÁ¤¾Æ(ÇÁ·Î¸Þ°¡ ÄÚ¸®¾Æ)
±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 15:55~16:20 Germline and somatic mutation tests: the same genes, but not the same testing ÀÌ¿ìâ(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 16:20~16:45 Somatic (Tumor) mutation test has a wider advantage than Germline mutation test ¼ºÃ¢¿Á(¼¿ï¾Æ»êº´¿ø)
Åä·Ð 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 16:45~16:50 Discussion, Q & A ()
±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 16:50~17:15 When is high time to prepare Survivorship care for Hereditary cancer patients? ½Åµ¿¿í(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 17:15~17:40 Fertility issue management for Hereditary cancer patients Ȳ±Ô¸®(¼¿ïÀÇ´ë)
±³À°½Ã°£ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 17:40~18:05 Meta-analysis result for Hereditary cancer patients ¼ÛÅÂÁ¾(¼º±Õ°üÀÇ´ë)
Åä·Ð 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 18:05~18:10 Discussion ()
±âŸ 01-19 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 18:10~18:15 Closing Remark ±è¹Î±Ô(¼º±Õ°üÀÇ´ë)